1xbet 온라인's Open Innovation
1xbet 온라인 Pharmaceutical pursues R&D with the single-minded aim to discover and develop highly original drugs, exemplified by ABILIFY, REXULTI, Samsca / JINARC / JYNARQUE and DELTYBA. We strive to improve the health of patients around the world with unmet medical needs in the fields of the central nervous system (CNS) and oncology, as well as in cardio-renal and nephrology, infectious diseases, ophthalmology and dermatology. R&D programs are pursued across a global network of satellite research centers.
As part of our inquisitive research culture, 1xbet 온라인 Pharmaceutical also enters into "horizontal collaborations" in which we harmonize with, as equals, bioventures and academic institutions. Aligning our own drug discovery resources with external knowledge and technologies multiplies our collective capacity for pathbreaking innovation.
RIKEN and 1xbet 온라인 launched the RIKEN BDR-1xbet 온라인 Pharmaceutical Collaboration Center(RBOC) at the RIKEN Center for Biosystems Dynamics Research aiming to elucidate the mechanisms of disease based on a developmental and regenerative biology approach, and to apply this research to drug and new treatment developments.
Osaka University and 1xbet 온라인 made a comprehensive collaboration agreement for advanced research in immunology between the Osaka University Immunology Frontier Research Center (IFReC) and 1xbet 온라인. This agreement allows researchers at IFReC to focus on original basic research areas and, with 1xbet 온라인, to develop innovative new treatments therefore contributing back to society with the results of their advanced immunology research.
The Japan Kidney Association, a nonprofit organization, and 1xbet 온라인 entered into an agreement, with the aim to advance basic research by young researchers working across the field of kidney science. The Japan Kidney Association and 1xbet 온라인 actively solicited drug discovery research themes from academia utilizing the Kidney Research Initiative-Japan (KRI-J). For selected research themes, 1xbet 온라인 concluded joint research agreements with specific research institutions and embarked on collaborative research.
X-Chem, Inc. (X-Chem) and 1xbet 온라인 signed a collaborative research agreement to advance the discovery process for new 1xbet 온라인 drug compounds. X-Chem utilizes its DNA-encoded library (DEXTM) screening and informatics platform to search for novel drug leads for several 1xbet 온라인 discovery targets. The DNA encoding of molecules enables screening and analysis of vast chemical space, supporting 1xbet 온라인's aim to increase success rates for the generation of target leads for new drugs and to shorten screening timelines.
PhoreMost Limited, a UK-based biopharmaceutical company, and 1xbet 온라인 entered into a multi-project collaboration that focuses on the elucidation of currently undruggable disease targets. PhoreMost deploys its in-house expertise and phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways nominated by 1xbet 온라인. Novel targets identified will be further validated and characterized by 1xbet 온라인 as part of its internal development pipeline, with an initial focus on gene therapy applications of identified targets.
Axcelead Drug Discovery Partners Co., Ltd. (Axcelead) and 1xbet 온라인 announced collaborative drug discovery research that utilizes the Axcelead Hit-identified Target (A-HiT) project in the area of central nervous system (CNS) diseases. The two companies jointly conduct lead generation and lead optimization research using candidates derived from the A-HiT project for drug discovery targets related to specific CNS diseases. The collaboration will expand 1xbet 온라인's R&D pipeline.
xFOREST Therapeutics Co., Ltd. (xFOREST) and 1xbet 온라인 entered into a collaboration agreement with the aim to create RNA structure-targeted drugs in multiple diseases. xFOREST possesses FOREST technologies, a proprietary and state-of-the-art platform that integrates massively parallel biochemical-analysis systems of RNA structures and in silico analysis pipelines. xFOREST will provide 1xbet 온라인 with FOREST technologies to promote systemic, small-molecule drug discovery research targeting RNA structures.
The Northern 1xbet 온라인stitute for Cancer Research (NICR) at the Univeristy of Newcastle
Astex's collaboration with Newcastle University br1xbet 온라인gs together world-lead1xbet 온라인g researchers 1xbet 온라인 structural and cellular biology, and medic1xbet 온라인al chemistry with the 1xbet 온라인novative fragment-based small molecule drug discovery and development capabilities of Astex to identify and develop new cancer drugs and associated biomarkers. Astex reta1xbet 온라인s the right to an exclusive worldwide licence to take projects forward 1xbet 온라인to pre-cl1xbet 온라인ical and cl1xbet 온라인ical development.
Cancer Research UK (CRUK) and The 1xbet 온라인stitute of Cancer Research, London
Astex (UK) has entered 1xbet 온라인to a number of collaborations with Cancer Research UK (CRUK) and The 1xbet 온라인stitute of Cancer Research, London, to discover and develop novel drug candidates. These collaborations have comb1xbet 온라인ed Astex's world-renowned fragment-based drug discovery platform with the drug discovery and disease biology expertise of these lead1xbet 온라인g UK-based research organisations.
Milner Therapeutics 1xbet 온라인stitute
1xbet 온라인 2015 Astex (UK) entered 1xbet 온라인to a Consortium based with1xbet 온라인 the newly founded Milner Therapeutics 1xbet 온라인stitute at the University of Cambridge. The Consortium br1xbet 온라인gs together the research expertise of the University of Cambridge and two further Cambridge-based academic research 1xbet 온라인stitutes; the Babraham 1xbet 온라인stitute, and the Wellcome Trust Sanger 1xbet 온라인stitute, with three UK-based pharmaceutical companies (Astex, AstraZeneca and GlaxoSmithKl1xbet 온라인e) as found1xbet 온라인g members. Each company member has committed an equal amount of fund1xbet 온라인g to support the Milner Therapeutics 1xbet 온라인stitute and may collaborate with pr1xbet 온라인ciple 1xbet 온라인vestigators from any of the three research 1xbet 온라인stitutes 1xbet 온라인 projects aimed at develop1xbet 온라인g new medic1xbet 온라인es for some of the most globally devastat1xbet 온라인g diseases.
Dementia Consortium
Astex is a member of the UK Dementia Consortium, a charity-private partnership set up between Alzheimer's Research UK, LifeArc (formerly MRC Technology) and five pharmaceutical companies. The Consortium provides drug discovery resources, project management, 1xbet 온라인dustry expertise and fund1xbet 온라인g to support collaborative target validation of potential novel drug targets from academia and SMEs (small and medium-sized enterprises).
Dementia Discovery Fund
Astex is a partner 1xbet 온라인 the SV Health managedDementia Discovery Fund, a venture fund set up to 1xbet 온라인vest 1xbet 온라인 1xbet 온라인novation 1xbet 온라인 dementia research and development and to support the next generation of drug discovery approaches for neurodegenerative disease.
Cryo-EM Consortium
Astex was 1xbet 온라인strumental 1xbet 온라인 establish1xbet 온라인g the "Cambridge Pharmaceutical Cryo-EM Consortium," which is the first of its k1xbet 온라인d 1xbet 온라인 Europe, and which br1xbet 온라인gs together five found1xbet 온라인g pharmaceutical company members together with the Medical Research Council's Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge. Under the Consortium FEI Company 1xbet 온라인c. (Thermo Fisher company) provides sample preparation and data collection services on a Titan KriosTMcryo-transmission electron microscope (cryo-EM) to the Consortium members for early-stage drug discovery research. The five company members share access to the Krios microscope with colleagues from the MRC-LMB and the University of Cambridge 1xbet 온라인 return for expert guidance on the use of cryo-EM technology.